Alto neuroscience presents data at the 2025 american society of clinical psychopharmacology annual meeting reinforcing safety and tolerability profile for alto-300 in major depressive disorder

Mountain view, calif.--(business wire)---- $anro #precisionpsychiatry--alto neuroscience, inc. (“alto”) (nyse: anro) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the american society of clinical psychopharmacology (ascp) annual meeting, in scottsdale, arizona, held may 27-30, 2025. alto-300, also known as agomelatine, is an oral, small molecule designed to act as a melatonin agonist and 5-ht2c antagonist be.
ALTO Ratings Summary
ALTO Quant Ranking